Fig. 2From: Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancerActuarial rates of toxicity. Actuarial rates of grade 2 or greater late genitourinary (a) and gastrointestinal (b) toxicityBack to article page